Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Ki67
PARP inhibitor
niraparib
ovarian cancer
rucaparib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
06 Feb 2023
06 Feb 2023
Historique:
received:
26
01
2023
revised:
03
02
2023
accepted:
03
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
There is compelling need for novel biomarkers to predict response to PARP inhibitors (PARPi) in BRCA wild-type (WT) ovarian cancer (OC). MITO 37 is a multicenter retrospective study aiming at correlating Ki67 expression at diagnosis with a clinical outcome following platinum treatment and PARPi maintenance. Clinical data were collected from high grade serous or endometroid BRCAWT OC treated with niraparib or rucaparib maintenance between 2010-2021 in 15 centers. Ki67 expression was assessed locally by certified pathologists on formalin-fixed paraffin embedded (FFPE) tissues. Median Ki67 was used as a cut-off. A total of 136 patients were eligible and included in the analysis. Median Ki67 was 45.7% (range 1.0-99.9). The best response to platinum according to median Ki67 was 26.5% vs. 39.7% complete response (CR), 69.1% vs. 58.8% partial response (PR), 4.4% vs. 1.5% stable disease (SD). The best response to PARPi according to median Ki67 was 19.1% vs. 36.8% CR, 26.5% vs. 26.5% PR, 26.5 vs. 25% SD, 27.9% vs. 16.2% progressive disease (PD). No statistically significant differences in progression free survival (PFS) and overall survival (OS) were identified between low and high Ki67. PFS and OS are in line with registration trials. Ki67 at diagnosis did not discriminate responders to PARPi.
Sections du résumé
BACKGROUND
BACKGROUND
There is compelling need for novel biomarkers to predict response to PARP inhibitors (PARPi) in BRCA wild-type (WT) ovarian cancer (OC).
METHODS
METHODS
MITO 37 is a multicenter retrospective study aiming at correlating Ki67 expression at diagnosis with a clinical outcome following platinum treatment and PARPi maintenance. Clinical data were collected from high grade serous or endometroid BRCAWT OC treated with niraparib or rucaparib maintenance between 2010-2021 in 15 centers. Ki67 expression was assessed locally by certified pathologists on formalin-fixed paraffin embedded (FFPE) tissues. Median Ki67 was used as a cut-off.
RESULTS
RESULTS
A total of 136 patients were eligible and included in the analysis. Median Ki67 was 45.7% (range 1.0-99.9). The best response to platinum according to median Ki67 was 26.5% vs. 39.7% complete response (CR), 69.1% vs. 58.8% partial response (PR), 4.4% vs. 1.5% stable disease (SD). The best response to PARPi according to median Ki67 was 19.1% vs. 36.8% CR, 26.5% vs. 26.5% PR, 26.5 vs. 25% SD, 27.9% vs. 16.2% progressive disease (PD). No statistically significant differences in progression free survival (PFS) and overall survival (OS) were identified between low and high Ki67. PFS and OS are in line with registration trials.
CONCLUSIONS
CONCLUSIONS
Ki67 at diagnosis did not discriminate responders to PARPi.
Identifiants
pubmed: 36831376
pii: cancers15041032
doi: 10.3390/cancers15041032
pmc: PMC9954459
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : University of Torino
ID : Ricerca Locale (ex-60%), Università di Torino 2020, to DS and GV
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
J Surg Oncol. 1997 Dec;66(4):230-6; discussion 236-7
pubmed: 9425325
Acta Histochem Cytochem. 2009 Dec 29;42(6):181-90
pubmed: 20126571
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Clin Cancer Res. 2015 Aug 15;21(16):3651-7
pubmed: 25501130
ESMO Open. 2022 Oct;7(5):100585
pubmed: 36156447
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
J Clin Oncol. 2023 Jan 20;41(3):609-617
pubmed: 36082969
Oncologist. 2021 Jan;26(1):e164-e172
pubmed: 33017510
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Ann Oncol. 2018 Jun 1;29(6):1366-1376
pubmed: 29750420
J Cancer. 2021 Jan 1;12(1):38-53
pubmed: 33391401
J Health Commun. 2015;20(11):1320-9
pubmed: 26161549
Cancers (Basel). 2022 Aug 11;14(16):
pubmed: 36010869
Ann Oncol. 2018 Aug 1;29(8):1784-1792
pubmed: 29767688
Clin Cancer Res. 2015 Oct 1;21(19):4257-61
pubmed: 26187614
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Nature. 2022 Dec;612(7941):634-636
pubmed: 36517683
J Clin Oncol. 2015 Nov 10;33(32):3836-8
pubmed: 26282651
APMIS. 2013 Dec;121(12):1177-86
pubmed: 23594232
Nature. 2022 Dec;612(7941):778-786
pubmed: 36517593
J Clin Oncol. 2020 Apr 10;38(11):1164-1174
pubmed: 32073956
Ann Oncol. 2020 Sep;31(9):1148-1159
pubmed: 32569725
J Obstet Gynaecol Res. 2005 Jun;31(3):268-76
pubmed: 15916666
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W128-32
pubmed: 18453628
Oncologist. 2020 Jan;25(1):e109-e119
pubmed: 31575788
J Cell Physiol. 2000 Mar;182(3):311-22
pubmed: 10653597
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Lancet Oncol. 2021 Dec;22(12):1721-1731
pubmed: 34715071